journal
MENU ▼
Read by QxMD icon Read
search

Lancet HIV

journal
https://www.readbyqxmd.com/read/28515015/collateral-damage-and-the-criminalisation-of-drug-use
#1
Lisa Maher, Thomas Crewe Dixon
No abstract text is available yet for this article.
May 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28515014/hiv-and-the-criminalisation-of-drug-use-among-people-who-inject-drugs-a-systematic-review
#2
Kora DeBeck, Tessa Cheng, Julio S Montaner, Chris Beyrer, Richard Elliott, Susan Sherman, Evan Wood, Stefan Baral
BACKGROUND: Mounting evidence suggests that laws and policies prohibiting illegal drug use could have a central role in shaping health outcomes among people who inject drugs (PWID). To date, no systematic review has characterised the influence of laws and legal frameworks prohibiting drug use on HIV prevention and treatment. METHODS: Consistent with PRISMA guidelines, we did a systematic review of peer-reviewed scientific evidence describing the association between criminalisation of drug use and HIV prevention and treatment-related outcomes among PWID...
May 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28501496/improved-life-expectancy-of-people-living-with-hiv-who-is-left-behind
#3
Ingrid T Katz, Brendan Maughan-Brown
No abstract text is available yet for this article.
May 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28501495/survival-of-hiv-positive-patients-starting-antiretroviral-therapy-between-1996-and-2013-a-collaborative-analysis-of-cohort-studies
#4
(no author information available yet)
BACKGROUND: Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. METHODS: We analysed data from 18 European and North American HIV-1 cohorts...
May 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28495563/resistance-matters-in-earnest
#5
Gary Maartens, Graeme Meintjes
No abstract text is available yet for this article.
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28495562/nucleoside-reverse-transcriptase-inhibitor-cross-resistance-and-outcomes-from-second-line-antiretroviral-therapy-in-the-public-health-approach-an-observational-analysis-within-the-randomised-open-label-earnest-trial
#6
Nicholas I Paton, Cissy Kityo, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, Joep J van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J Easterbrook, Peter Mugyenyi, A Sarah Walker
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV. METHODS: We did an observational analysis of additional data from a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa...
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28479492/durability-of-viral-suppression-with-first-line-antiretroviral-therapy-in-patients-with-hiv-in-the-uk-an-observational-cohort-study
#7
Jemma O'Connor, Colette Smith, Fiona C Lampe, Margaret A Johnson, David R Chadwick, Mark Nelson, David Dunn, Alan Winston, Frank A Post, Caroline Sabin, Andrew N Phillips
BACKGROUND: The length of time that people with HIV on antiretroviral therapy (ART) with viral load suppression will be able to continue before developing viral rebound is unknown. We aimed to investigate the rate of first viral rebound in people that have achieved initial suppression with ART, to determine factors associated with viral rebound, and to use these estimates to predict long-term durability of viral suppression. METHODS: The UK Collaborative HIV Cohort (UK CHIC) Study is an ongoing multicentre cohort study that brings together in a standardised format data on people with HIV attending clinics around the UK...
May 4, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28479491/long-term-durability-of-hiv-viral-load-suppression
#8
Nila J Dharan, David A Cooper
No abstract text is available yet for this article.
May 4, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28457797/correction
#9
(no author information available yet)
No abstract text is available yet for this article.
April 27, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28431924/racial-disparities-in-hiv
#10
Richard Davies Burt, Sara Nelson Glick
No abstract text is available yet for this article.
April 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28431923/sources-of-racial-disparities-in-hiv-prevalence-in-men-who-have-sex-with-men-in-atlanta-ga-usa-a-modelling-study
#11
Steven M Goodreau, Eli S Rosenberg, Samuel M Jenness, Nicole Luisi, Sarah E Stansfield, Gregorio A Millett, Patrick S Sullivan
BACKGROUND: In the USA, men who have sex men (MSM) are at high risk for HIV, and black MSM have a substantially higher prevalence of infection than white MSM. We created a simulation model to assess the strength of existing hypotheses and data that account for these disparities. METHODS: We built a dynamic, stochastic, agent-based network model of black and white MSM aged 18-39 years in Atlanta, GA, USA, that incorporated race-specific individual and dyadic-level prevention and risk behaviours, network attributes, and care patterns...
April 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416197/pre-exposure-prophylaxis-is-approved-in-scotland
#12
Rak Nandwani
No abstract text is available yet for this article.
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416196/another-statin-option-in-hiv
#13
Philip E Tarr, Helen Kovari
No abstract text is available yet for this article.
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#14
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28411091/comparison-of-dynamic-monitoring-strategies-based-on-cd4-cell-counts-in-virally-suppressed-hiv-positive-individuals-on-combination-antiretroviral-therapy-in-high-income-countries-a-prospective-observational-study
#15
Ellen C Caniglia, Lauren E Cain, Caroline A Sabin, James M Robins, Roger Logan, Sophie Abgrall, Michael J Mugavero, Sonia Hernández-Díaz, Laurence Meyer, Remonie Seng, Daniel R Drozd, George R Seage, Fabrice Bonnet, Francois Dabis, Richard D Moore, Peter Reiss, Ard van Sighem, William C Mathews, Julia Del Amo, Santiago Moreno, Steven G Deeks, Roberto Muga, Stephen L Boswell, Elena Ferrer, Joseph J Eron, Sonia Napravnik, Sophie Jose, Andrew Phillips, Amy C Justice, Janet P Tate, John Gill, Antonio Pacheco, Valdilea G Veloso, Heiner C Bucher, Matthias Egger, Hansjakob Furrer, Kholoud Porter, Giota Touloumi, Heidi Crane, Jose M Miro, Jonathan A Sterne, Dominique Costagliola, Michael Saag, Miguel A Hernán
BACKGROUND: Clinical guidelines vary with respect to the optimal monitoring frequency of HIV-positive individuals. We compared dynamic monitoring strategies based on time-varying CD4 cell counts in virologically suppressed HIV-positive individuals. METHODS: In this observational study, we used data from prospective studies of HIV-positive individuals in Europe (France, Greece, the Netherlands, Spain, Switzerland, and the UK) and North and South America (Brazil, Canada, and the USA) in The HIV-CAUSAL Collaboration and The Centers for AIDS Research Network of Integrated Clinical Systems...
April 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28411090/less-frequent-cd4-monitoring-in-virologically-suppressed-hiv
#16
James McMahon, Suzanne M Crowe
No abstract text is available yet for this article.
April 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28366707/relative-effects-of-antiretroviral-therapy-and-harm-reduction-initiatives-on-hiv-incidence-in-british-columbia-canada-1996-2013-a-modelling-study
#17
Bohdan Nosyk, Xiao Zang, Jeong E Min, Emanuel Krebs, Viviane D Lima, M-J Milloy, Jean Shoveller, Rolando Barrios, P Richard Harrigan, Thomas Kerr, Evan Wood, Julio S G Montaner
BACKGROUND: Antiretroviral therapy (ART) and harm reduction services have been cited as key contributors to control of HIV epidemics; however, the specific contribution of ART has been questioned due to uncertainty of its true efficacy on HIV transmission through needle sharing. We aimed to isolate the independent effects of harm reduction services (opioid agonist treatment uptake and needle distribution volumes) and ART on HIV transmission via needle sharing in British Columbia, Canada, from 1996 to 2013...
March 30, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28262574/health-adjusted-life-expectancy-in-hiv-positive-and-hiv-negative-men-and-women-in-british-columbia-canada-a-population-based-observational-cohort-study
#18
Robert S Hogg, Oghenowede Eyawo, Alexandra B Collins, Wendy Zhang, Shahab Jabbari, Mark W Hull, Viviane Dias Lima, Tareq Ahmed, Claire E Kendall, Keri N Althoff, Amy C Justice, Rolando Barrios, Jeannie Shoveller, Julio S G Montaner
BACKGROUND: We sought to understand whether people living with HIV (PLHIV) ever on highly active antiretroviral therapy (ART) follow a pattern where morbidity is compressed into the last years of life or lessened as people age. We aimed to estimate health-adjusted life expectancy (HALE) among adults living with and without HIV, and examine dependency between causes of comorbidities. METHODS: The Comparative Outcomes and Service Utilization Trends (COAST) study is a retrospective cohort of adults (≥20 years) including all known PLHIV and a 10% random sample of the general population of British Columbia, and with longitudinal data spanning from April 1, 1996, to Dec 31, 2012...
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28262573/liver-disease-and-healthy-life-expectancy-with-hiv
#19
Hugo Perazzo, Paula M Luz
No abstract text is available yet for this article.
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28259777/switching-from-tenofovir-disoproxil-fumarate-to-tenofovir-alafenamide-coformulated-with-rilpivirine-and-emtricitabine-in-virally-suppressed-adults-with-hiv-1-infection-a-randomised-double-blind-multicentre-phase-3b-non-inferiority-study
#20
Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Bernard Vandercam, Joseph de Wet, Jürgen Rockstroh, Adriano Lazzarin, Bart Rijnders, Daniel Podzamczer, Anders Thalme, Marcel Stoeckle, Danielle Porter, Hui C Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao
BACKGROUND: Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks. We investigated the efficacy, safety, and tolerability of switching to a single-tablet regimen containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate. METHODS: In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-1-infected adults were screened and enrolled at 119 hospitals in 11 countries in North America and Europe...
March 1, 2017: Lancet HIV
journal
journal
49635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"